The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.
 
Nicholas Cost
Employment - Janssen (I)
 
Lindsay Renfro
No Relationships to Disclose
 
Matthew Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - Adicet Bio; AVEO; Exelixis; Merck
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst)
 
Ana Molina
No Relationships to Disclose
 
Mamta Parikh
Consulting or Advisory Role - Bicycle Therapeutics; Bristol Myers Squibb; Exelixis; Pfizer; Pfizer-Myovant; Sanofi/Aventis; Totus Medicines
Research Funding - Gilead Sciences; Karyopharm Therapeutics (Inst)
 
Luke Pater
No Relationships to Disclose
 
Ian Tfirn
No Relationships to Disclose
 
Elizabeth Mullen
No Relationships to Disclose
 
Peter Ehrlich
No Relationships to Disclose
 
Elisabeth Tracy
No Relationships to Disclose
 
John Kalapurakal
No Relationships to Disclose
 
Jeffrey Dome
No Relationships to Disclose
 
James Geller
Research Funding - Pfizer